Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease
Professor Martin Wagenmann describes the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP.
Learning objectives
- Review the role of type 2 inflammation underlying the pathophysiology of CRSwNP and the mechanisms of action of biologics approved for severe/uncontrolled CRSwNP
- Understand the comparative efficacy and recently published real-world effectiveness of biologics approved for patients with severe/uncontrolled CRSwNP
Description
Join global experts Martin Wagenmann, MD, PhD, and Eugenio De Corso, MD, PhD, for an educational program on type 2 inflammation underlying CRSwNP and discussions of biologic efficacy and real-world effectiveness in patients with CRSwNP. Prof. Wagenmann will describe the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP, and Prof. De Corso will discuss indirect comparisons of biologics approved for patients with uncontrolled CRSwNP and emerging real-world effectiveness of biologics for patients with CRSwNP.
About this expert
Martin Wagenmann
Head of Rhinology, Allergy, and Endoscopic Skull Base Surgery and Head of the Research Laboratory in the ENT Department | University Hospital of Düsseldorf, Germany
See author’s profileRelated resources
